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Complex interactions between androgen and estrogen (E2) regulate
prostatic development and physiology. We analyzed the early effects
of a high single dose of E2 (25 mg/kg body weight) and castration
(separately or combined) on the adult 90-day-old male Wistar rat
ventral prostate. Androgen levels, prostate weight, and the variation in
the relative and absolute volume of tissue compartments and apoptotic
indices were determined for 7 days. Castration and exogenous E2
markedly reduced ventral prostate weight (about 50% of the control),
with a significant reduction in the epithelial compartment and in-
creased stroma. The final volume of the epithelium was identical at
day 7 for all treatments (58.5% of the control). However, E2 had an
immediate effect, causing a reduction in epithelial volume as early as
day 1. An increase in smooth muscle cell volume resulted from the
concentration of these cells around the regressing epithelium. The
treatments resulted in differential kinetics in epithelial cell apoptosis.
Castration led to a peak in apoptosis at day 3, with 5% of the epithelial
cells presenting signs of apoptosis, whereas E2 caused an immediate
increase (observed on day 1) and a sustained (up to day 7) effect. E2
administration to castrated rats significantly increased the level of
apoptosis by day 3, reaching 9% of the epithelial cells. The divergent
kinetics between treatments resulted in the same levels of epithelial
regression after 7 days (~30% of control). These results show that E2
has an immediate and possibly direct effect on the prostate, and
anticipates epithelial cell death before reducing testosterone to levels
as low as those of castrated rats. In addition, E2 and androgen
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Androgens are required for the growth
and physiology of the prostate. The circulat-
ing androgens are testosterone (T) and dihy-
drotestosterone (DHT). The former is pro-
duced mainly by the testis (~95%) and the
adrenal gland (~5%) (1). The conversion of
T to the more potent androgen DHT by the
enzyme 5α-reductase occurs in the testis and
other tissues, including the prostate. Although
the normal prostate has been reported not to
contribute to the circulating levels of DHT
(2), there may be a contribution by this organ
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in subjects with a hypertrophic prostate (3).
Both T and DHT bind to the same androgen
receptor (AR) with different affinities and
apparently with different transcriptional ac-
tivities.
Circulating T, but not DHT, is converted
to estrogen (E2) in several tissues by the
enzyme aromatase. Apart from interest in
the physiological role of E2 in males, these
hormones have gained importance because
they may have deleterious effects on the
formation of the male reproductive organ
and on reproductive performance and be-
havior. Indeed, a hypothesis has been pro-
posed whereby embryonic exposure to E2 is
implicated as the causative agent of cryp-
torchidism, testis cancer, hypospadia, and a
low sperm count (4).
Although the prostate is an androgen-de-
pendent tissue, its physiology and pathology
are also influenced by E2. Accordingly, E2
receptors α and ß are expressed in the prostatic
stroma and epithelium, respectively (5,6). Fur-
thermore, aromatase has been identified in the
human prostate, suggesting that the prostate is
a site of aromatization and a possible source of
E2 (7). These data suggest that E2 may be
produced locally in the prostate gland and may
influence both epithelial and stromal cells via
its two receptors. However, E2 has a general
anti-androgen effect, and negatively regulates
the hypothalamus-hypophysis-testis axis,
thereby reducing androgen production by
Leydig cells and causing involution of the
prostatic epithelium and growth of the stroma
in adult animals (6,8).
The effects of E2 on the prostate are
complex. Long-term treatment of adult rats
with E2 causes prostatic involution (9) and
ultimately leads to epithelial squamous meta-
plasia (10). In castrated dogs, E2
 
(8 mg/dog
per week) has a proliferative effect on both
stroma and epithelium (11). When adminis-
tered to neonates, E2
 
causes nonmonotonic
permanent changes in the prostate, with a
low dose increasing puberal growth while a
high dose has inhibitory effects (9,12). Fur-
thermore, E2 administration during the neo-
natal phase causes prostatic hyperplasia and/
or dysplasia earlier in adulthood, as well as
more frequent prostatitis (13-15). In the guin-
ea pig, E2 has little ability to compete with
DHT for AR but is effective in lowering the
serum concentrations of T (16).
Since aromatization is the only source of
E2 in the male organism, aromatase knock-
out mice would provide an excellent model
system for studying the action of endoge-
nous E2 in the prostate. Indeed, in such mice
there is enlargement of the prostate, with an
equal contribution from the epithelium and
stroma based on histological analysis (17).
Although this could indicate that E2 inhib-
ited prostatic growth, serum and tissue con-
centration of androgens, as well as AR ex-
pression and prolactin concentrations, were
increased in these mice. Under these condi-
tions, a direct effect of E2 on the prostate
could not be conclusively demonstrated.
To assess the direct effects on the prostate,
Jarred et al. (18) developed an in vitro assay
using cultured whole ventral prostates from
neonates and testing the effect of E2 in a
constant androgen environment, thus avoid-
ing the anti-androgen effect of E2. Under
these conditions, E2 inhibited prostate growth,
epithelial branching and ductal canalization.
Bianco et al. (19) also examined the direct
effect of E2 on prostatic growth by using the
hypogonadal (hpg) mouse model which is
gonadotropin deficient, and showed that E2
caused proliferation and prostatic growth when
administered to adult mice. However, the re-
sults also proved that part of the prostatic
growth was associated with dysplastic epithe-
lium. Epithelial growth in male and female
reproductive organs occurs through paracrine
mechanisms mediated by stromal receptors.
Cunha et al. (20) showed that androgen-in-
duced epithelial proliferation in the prostate
gland is indirect, being mediated by mesen-
chymal/stromal AR-positive cells.
Taken together, these studies show that
the hormonal control of prostatic develop-
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ment and function is complex and depends
on both a balance between steroid hormones
and epithelial-stromal interactions. The path-
ways in this network are still poorly under-
stood and their analysis is hampered by the
predominant effect of androgens.
Androgen deprivation elicited by surgi-
cal or chemical castration induces apoptosis
in the prostatic epithelium. In the ventral
prostate of the rat, epithelial apoptosis reaches
its peak three days after androgen withdraw-
al (21). By seven days after surgical castra-
tion the rat prostate undergoes rapid involu-
tion. Basal and secretory cellular subtypes
persist. However, the number of glandular
cells is significantly reduced (a 66% de-
crease) (22) and secretory activity is se-
verely attenuated.
More recently, a study on tissue recombi-
nants using epithelial cells from the testicu-
lar feminization mutant mouse demonstrated
that epithelial cell apoptosis is not a direct
response to low levels of T, but results from
paracrine interactions with the stromal cells
(21). In the proposed model, the lack of
androgen stimulation would result in either
impairment of the production of epithelial
survival factors usually produced by the
stroma or the production of death signals,
which would induce epithelial cell death.
Epithelial apoptosis in the rat ventral pros-
tate is secondary to the restriction in blood
supply (and hence a diminished nutrient and
a putative hypoxic condition) and apoptosis
of endothelial cells. Endothelial cells un-
dergo apoptosis as early as 24 h after castra-
tion (23). Revascularization is a key event in
the restoration of prostatic physiology after
androgen administration to castrated animals
and emphasizes the importance of blood
vessels in the prostate (24).
To investigate the early effects of E2 on
the prostate, in the present study we admin-
istered a high dose of E2 to castrated and
non-castrated rats and examined the behav-
ior of different tissue compartments and the
induction of epithelial cell death. Histologi-
cal analyses associated with unbiased stere-
ology and determination of the apoptotic
index were done in the rat ventral prostate
over a 7-day period. This approach allowed
us to identify a threshold for epithelial re-
gression within the first week of androgen
deprivation and demonstrated that E2 and
castration contributed to apoptotic cell death
via distinct and independent mechanisms.
Material and Methods
Animal protocol
Sixty adult male Wistar rats (90 days old)
were maintained in a controlled environ-
ment with free access to food and water. The
experiments were carried out according to
the Guide for Care and Use of Laboratory
Animals and were approved by the Commit-
tee for Ethics in Animal Experimentation of
UNICAMP.
A single dose of 17ß-estradiol (E2; Sigma,
St. Louis, MO, USA; 0.0367 mmol, corre-
sponding to a high dose of 25 mg/kg body
weight) was injected subcutaneously in 0.4 ml
of corn oil. Control rats received only corn oil.
The rats were divided into four experimental
groups: intact rats receiving vehicle (control),
non-castrated rats treated with E2, castrated
rats treated with E2, and castrated rats with no
further treatment. Analyses were performed
on days 1, 2, 3, 5, and 7 (N = 3).
At 91, 92, 93, 95, and 97 days of age, the
different groups of rats were weighed and
then killed by cervical dislocation within 5 s
after being removed from their cages. The
testis, seminal vesicle, ventral prostate, and
coagulating gland (the ventral lobe and co-
agulating gland were carefully separated from
the other lobes and from the seminal vesicle,
respectively) were excised and weighed. The
ventral prostate was dissected out and imme-
diately fixed by immersion in 4% formalde-
hyde in phosphate-buffered saline for 24 h.
The samples were then washed, dehydrated
and embedded in JB4 historesin (Leica,
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Nussloch, Heildelberg, Germany) for ste-
reological analysis.
Total plasma testosterone levels
Plasma T levels were estimated by radio-
immunoassay. Blood samples were obtained
by cardiac puncture immediately before
death. The plasma was separated by cen-
trifugation and stored at -20ºC for subse-
quent hormone assays. T concentration was
measured in plasma samples using a Coat-A-
Count kit (Diagnostic Products, Los Ange-
les, CA, USA). Serum samples were assayed
in duplicate and sensitivity to T was 0.94 ng/
dl. The intra-assay and interassay variation
was 5.36 and 5.10%, respectively.
Stereological analysis
Two-micrometer sections were obtained
and stained with hematoxylin and eosin. Six
microscope fields were analyzed in sections
from at least 2 rats from each group. The
sections were photographed and stereology
was done using Weibel’s system and a 168-
point grid, as applied to the rat ventral prostate
by Huttunen et al. (25). Microscopic fields
representing predominantly proximal or distal
ductal regions were avoided because of the
predominance of muscular and epithelial com-
partments in each of these regions, respec-
tively (26). The volume densities of the epithe-
lium, lumen, smooth muscle, and non-muscu-
lar stroma were determined. The total stroma
was the sum of the smooth muscle and non-
muscular stroma. As part of an exploratory
analysis, the total volume of each of these
compartments was determined based on the
mean prostatic weight for each group, consid-
ering a 1:1 weight to volume correlation (25).
Detection of apoptosis and determination of
the apoptotic index
DNA fragmentation was detected using a
fluorescein apoptosis detection system (Pro-
mega, Madison, WI, USA) according to manu-
facturer instructions. The apoptotic nuclei were
identified using a Zeiss Axioskop microscope
(Jena, Germany) equipped for fluorescence
microscopy and micrographs were obtained
using Kodak 400 Kodacolor film.
Historesin sections were subjected to
Feulgen’s reaction. Sections were subjected
to hydrolysis with 4 N HCl for 75 min and
then treated with Schiff’s reagent for 40 min.
After extensive washing, the sections were
dehydrated and mounted in Canada balsam.
Six microscopic fields from at least 2 rats
were analyzed and the apoptotic index was
determined by dividing the number of apop-
totic nuclei by the total number of nuclei
found in the microscope field, using a 40X
objective. Apoptotic nuclei were identified
by the characteristic pyknosis and/or nuclear
fragmentation, as reported by Kerr and Searle
(27). The number of nuclei counted was
1290 to 2657 for the different experimental
conditions. Only the epithelium was consid-
ered for these counts.
Statistical analysis
Data are reported as means ± SEM, where
appropriate. One-way analysis of variance
(ANOVA) was used to compare the meas-
urements obtained after each treatment with
control measurements. Differences were con-
sidered significant when P ≤ 0.05.
Results
Table 1 shows the variation in body,
testis and accessory gland weights on day 7
after the different treatments. Castration or
the administration of E2 to non-castrated
and castrated rats caused small, nonsignifi-
cant reductions in body weight. E2 signifi-
cantly reduced testis weight, whereas E2 and
castration caused similar reductions in ac-
cessory gland weight. Although significant,
the reduction in seminal vesicle weight was
less pronounced than in the other glands
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after treatment with E2. The administration
of E2 to castrated rats did not affect the
reduction in prostatic weight caused by cas-
tration alone.
Table 2 shows the quantitative data for
total plasma T concentration after castration
and treatment with E2. Castration almost
completely reduced plasma T levels 24 h
after surgical removal of the testes. Treat-
ment with E2 also resulted in a marked de-
crease in plasma T levels. However, there
was a residual amount of T (5-6% of the
control value) 24 and 48 h after E2 adminis-
tration. T was not detected after 72 h.
Histological analysis of the rat ventral
prostate revealed a simple, cylindrical epi-
thelium with basal nuclei. The stroma was
scarce, with few smooth muscle cells (SMC)
and fibroblasts (Figure 1A). Treatment with
E2 resulted in shorter epithelial cells at day
7. The SMC formed a dense bundle below
the epithelium (Figure 1B). Seven days of
Table 2. Total serum testosterone concentration.
Days after castration
1 2 3 5 7
Control 350.5 ± 61.1
Castrated <0.94a <0.94a <0.94a <0.94a <0.94a
E2 treated 11.15 ± 5.1* 17.7 ± 3.4* <0.94a <0.94a <0.94a
Data are reported as means ± SEM in ng/dl.  aBelow the detection limit.
*P < 0.001 compared to control (one-way analysis of variance).
androgen deprivation by surgical castration
resulted in loss of the apical cytoplasm and
shorter epithelial cells. The stroma was more
prominent, with a denser array of SMC,
fibroblasts and other cell types (Figure 1C).
Castrated rats treated with E2 showed a his-
tological organization intermediate between
that seen in castrated rats and E2-treated
rats, especially with respect to the SMC (Fig-
ure 1D).
Stereology was used to follow the changes
of different tissue compartments in the vari-
ous hormonal situations. Treatment with E2
resulted in a marked reduction in the volume
density of the epithelial compartment two
days after the beginning of the treatment
(from 47 to ~32%). This loss was maintained
up to day 5 and was then partially restored at
day 7 (Figure 2A). E2 caused an immediate
increase in the volume density of the lumen
by day 2 followed by a progressive decrease
up to day 7 (Figure 2B). Castration and E2
Table 1. Effect of hormonal conditions on the body weight, testis and accessory gland weight in male rats 7
days after estrogen treatment or castration.
Group Body Testes Ventral Seminal Coagulating
prostate vesicle gland
Control 337.0 ± 11.0 3.67 ± 0.09 0.585 ± 0.003 0.598 ± 0.035 0.370 ± 0.014
Castrated 292.6 ± 5.24 - 0.277 ± 0.007* 0.330 ± 0.013* 0.237 ± 0.001*
E2 treated 308.3 ± 2.33 2.72 ± 0.05* 0.293 ± 0.014* 0.403 ± 0.026* 0.262 ± 0.010*
Castrated + 291.6 ± 8.33 - 0.281 ± 0.006* 0.397 ± 0.026* 0.296 ± 0.023*
E2 treated
Data are reported as means ± SEM in grams. E2 = estradiol.
*P < 0.005 compared to control (one-way analysis of variance).
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administration to castrated rats resulted in
no such variation of the lumen, although
there was a slight, progressive decrease in its
volume density (Figure 2B).
Castration and E2 increased the volume
density of the stroma (Figure 2C), and there
was also a progressive increase in stromal
volume after day 2, with a pronounced con-
tribution of the SMC in all hormonal condi-
tions when compared to control (Figure
2C,D).
The absolute volume showed more dra-
matic changes in the prostatic tissue com-
partments. Castration, E2, and E2 adminis-
tration to castrated rats resulted in a decrease
in the absolute volume of the epithelium
(Figure 2E). E2 caused an increase in the
luminal compartment at day 2 followed by a
progressive reduction up to day 7. A reduc-
tion was noted in the luminal (Figure 2F),
stromal (Figure 2G) and SMC (Figure 2H)
compartments, regardless of treatment, com-
pared to control.
TUNEL labeling was used to detect DNA
strand breaks, a reliable indicator of apopto-
sis in the rat ventral prostate (28). There was
virtually no apoptosis in the control rats
(Figure 3A), but marked apoptosis was seen
in E2-treated (Figure 3B) and castrated (Fig-
ure 3C) rats. The apoptotic indices revealed
different kinetics for cell death for each treat-
ment (Figure 4). Castration resulted in a
peak of apoptosis on day 3. Treatment with
E2 resulted in apoptotic cell death that
reached a plateau on day 2 and was main-
tained up to day 5. The apoptotic index
observed on day 3 was similar to that ob-
tained by castration. E2 administration to
castrated rats resulted in an increase in apop-
totic cell death that was significantly greater
than that observed after castration alone (P <
0.05). Curiously, the curve profile corre-
sponded to a summation of the results ob-
tained by castration and treatment with E2
separately.
Discussion
Prostate development and function are
influenced by E2. These hormones exert a
general effect by negatively regulating the
hypothalamus-hypophysis-testis axis and
then reducing T production by the testis
(29). However, the identification of E2 re-
ceptors α and ß in prostatic cells indicates
that E2 might have a direct effect on the
prostate. This conclusion is further supported
by the fact that the prostate is also able to
convert T to E2 (7). Determining the effects
of E2 on the prostate is important because E2
is a necessary agent in the control of andro-
gen-insensitive prostate cancer (30,31).
Figure 1. Hematoxylin and eosin-stained sections of the rat ventral prostate 7 days after
receiving estrogen (E2) or being castrated. A, The control prostate shows characteristic
cylindrical epithelial cells (ep) with a basal nucleus and a prominent nucleolus. The stroma is
reduced and shows a few elongated smooth muscle cells (smc, asterisk) beneath the
epithelium. B, E2 treatment resulted in reduction of the apical cytoplasm and an increase in
the stroma. smc occupied a larger area of the stroma and appeared to be hyperplastic. C,
Castration resulted in shortening of the epithelial cells and thickening of the stroma, with a
greater contribution by smc, blood vessels and other cell types. D, E2 administration to
castrated rats did not change the basic aspects seen in castrated animals, including those
related to the smc (asterisk). Bar = 25 µm (A-D).
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Figure 2. Stereological analysis
of the rat ventral prostate com-
partments. A-D correspond to
the relative volume (%) of each
compartment and E-H are the
absolute volume (ml) of each
compartment. CT = control; E2
= control rats treated with es-
trogen; CAS = castrated rats;
CAS + E2 = castrated rats
treated with E2; 1-7 represent
the days after the beginning of
treatment. The indices in the fig-
ure indicate values statistically
different from the control (a,
castrated rats treated with E2;
b, castrated rats; c, E2-treated
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and stroma, while high doses have an inhib-
itory effect (9,12,34).
In the present investigation, we studied
the early effects of a high dose of E2 in adult
rats and compared them with those promoted
by androgen ablation following castration.
We used a high dose in order to exacerbate
the effects of E2 on the prostate and to detect
possible acute responses in the different tis-
sue compartments. One pitfall of this ap-
proach is that at high concentrations E2 may
compete with T and DHT for the AR, at least
in vitro (16). Such antagonist effect cannot
be excluded here and may have contributed
to the observed effects of E2.
E2 caused a general reduction in testicu-
lar weight, in agreement with the ability of
this hormone to reduce gonadotropin secre-
tion. In addition, E2 also reduced the ventral
prostate and coagulating gland to an extent
that was comparable to the effect of castra-
tion. The seminal vesicle was also affected,
but to a lesser extent.
All treatments reduced the relative and
absolute volume of the epithelium, although
the final absolute volume was similar after 7
days for each treatment, and corresponded to
~32% of the organ. However, E2 caused a
progressive reduction in epithelial volume
that was observed as early as 24 h after
hormone administration. This contrasted with
the reduction in epithelial volume caused by
castration, which appeared later and was
more evident on days 5 and 7. Thus, the
kinetics of epithelial volume reduction dif-
fered between castration and treatment with
E2. The regressive effect of the high dose of
E2 used here contrasts with the stimulatory
action of a low dose in castrated rats (35).
The epithelial reduction resulted partly
from epithelial cell loss by apoptosis. These
results agree with previous studies indicat-
ing that epithelial apoptosis peaks on the
third day after castration (36). In contrast,
the high dose of E2 increased the apoptotic
index within 24 h after dosing; there was an
additional slight increase after 48 h, which
Figure 3. Detection of DNA frag-
mentation in the rat ventral pros-
tate. Control rats (A) showed no
reaction, while treatment with
estrogen (B) and castration (C)
resulted in DNA fragmentation
(arrows). Representative micro-







































Figure 4. Apoptotic indices for
prostatic epithelial cells. Castra-
tion resulted in a peak of apop-
totic cell death on day 3. E2
caused the premature death of
epithelial cells and showed a
sustained effect. E2 administra-
tion to castrated rats resulted in
an increased incidence of apop-
tosis, but preserved the peak
apoptotic nuclei on day 3. CT =
control; E2 = rats treated with
estrogen; CAS = castrated rats;
CAS + E2 = castrated rats
treated with E2. The indices in
the figure indicate values statistically different from the control (a, castrated rats treated
with E2; b, castrated rats; c, E2-treated rats) at P < 0.05 (one-way analysis of variance).
When administered neonatally, E2 causes
several defects in prostatic development, in-
cluding an increased susceptibility to pros-
tatitis (15,32) and to the occurrence of pros-
tatic metaplasia (33). Long-term treatment
of adult rats with E2 causes prostatic involu-
tion (9) and ultimately leads to epithelial
squamous metaplasia (10). Moreover, there
appears to be a dose-dependent variation in
the effects of E2. Low doses have a stimula-






Braz J Med Biol Res 38(4) 2005
Early effects of E2 on the ventral prostate
was then maintained up to 72 h post-treat-
ment. The rapidity of this response to E2
suggests that this hormone may have a direct
action on epithelial cells (which express E2
receptor ß), in contrast to apoptosis induced
by androgen ablation, which involves para-
crine regulation via stromal cells (21). E2
had an additive effect on the apoptotic index
obtained following castration, which sug-
gests that the two treatments induced epithe-
lial apoptosis through distinct and probably
independent apoptotic pathways.
It is unclear why the increase in apoptosis
seen in castrated rats treated with E2 did not
result in a greater reduction in epithelial
volume and ventral prostate weight after 7
days when compared to that caused by either
castration or E2 treatment alone. Indeed,
there was no difference in the luminal, stroma
or SMC compartments of the rat ventral
prostate on day 7 after either treatment.
Castration, E2 administration, and E2
administration to castrated rats also increased
the relative volume and slightly decreased
the absolute volume of the SMC. A similar
reduction in SMC volume after castration
has been reported before (37) and was sug-
gested to be the result of cellular atrophy or
cell loss by apoptosis.
Zhao et al. (38) reported that the most
obvious alteration in the ventral prostate in
response to E2 was a reduction in luminal
volume. In addition we have also observed a
sudden increase in the volume of the lumen.
This oscillation in luminal volume was spe-
cific for E2 and may be attributed to an
immediate loss of the epithelium rather than
to an increased secretory activity. Lumen
regression will be seen later, when the organ
compensates for epithelial inactivity and loss.
Since E2 has an anti-androgen effect that
is mediated by down-regulation of the hypo-
thalamus-hypophysis-testis axis, it is diffi-
cult to define the direct effects of this hor-
mone on the prostate. In an in vitro system,
E2 diminished prostatic growth without af-
fecting cell proliferation (18). A stimulatory
effect of E2 on the male accessory sex glands
in hypogonadal mice has been reported (19).
This growth reflected increments in the epi-
thelium of the anterior prostate and seminal
vesicle, but not in the ventral prostate. Squa-
mous metaplasia and inflammation were
common responses to E2 in the absence of
androgen.
It is worth mentioning at this point that
we have assessed the number of PCNA-
positive cells in the experimental groups
used here and found that castration, E2 treat-
ment and E2 plus castration resulted in the
complete elimination of proliferative cells
(data not shown).
The present results clearly show that E2
has an immediate effect on the prostatic
epithelium, and induces apoptotic cell death
as early as 24 h after treatment. By this time
point, circulating T levels have been reduced
to about 5%. However, the effect of E2
cannot be attributed solely to a decrease in T
levels. Were this the case, the cell death
kinetics would be expected to be similar to
that observed for androgen ablation.
Defining the molecular mechanism of E2
action on the prostate has proven difficult,
despite the growing number of experimental
models and treatment protocols. The use of a
high dose of E2 was helpful in defining the
initial early effects of E2 and represents a
good model system for investigating the
mechanisms involved in the direct action of
E2 in the prostate gland. Refinement of the
protocol used here could be helpful for dis-
tinguishing between the effects of E2 on the
hypothalamus-hypophysis-testis axis, its ac-
tions as an antagonist competing with T and
DHT for the AR, and the involvement of E2
receptor ß. Further attempts to characterize
the effect of E2 and castration on the pros-
tate must consider that, while castration
causes an important increase, E2 causes a
marked reduction in protein synthesis in both
epithelium and stroma (39).
Androgen ablation and a high dose of E2
cause prostatic epithelial cell apoptosis
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through distinct and apparently independent
pathways. Prostatic involution is dependent
on early effects that are more prominent in
the epithelium, with minor contributions from
the stroma and SMC. Even though E2 caused
an accelerated loss of the epithelial cells and
this effect was exacerbated in E2-treated
castrated rats, there was a threshold for epi-
thelial loss within the first week. Further
weight loss will depend on other alterations
of the gland that cannot be anticipated by E2.
Most likely, E2 was unable to anticipate later
stromal changes seen in castrated animals
(37,40), which may be necessary for further
prostatic involution.
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